Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nokia Corp (NOK) vs Zoetis Inc (ZTS) Price & Performance

Nokia CorpTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Nokia Corp vs Zoetis Inc — how do they compare? Nokia Corp trades at $10.35 (market cap $56.99B), while Zoetis Inc trades at $74.42 (market cap $30.20B). The key difference: Nokia Corp is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 66 Days and Zoetis Inc for 70 Days on average.

NOKZTS
Market Cap
$56.99B$30.20B
Volume
69,968,2046,175,327
Sector
TechnologyHealth
52-Week High
$16.83$147.53
52-Week Low
$5.18$69.09
Typical Hold Time
66 Days70 Days
Enterprise Value
$55.01B$37.76B
Dividend Yield
1.61%2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nokia Corp

Nokia (NOK) trades at $10.285, down 3.15% today, with a bearish technical signal from moving averages and neutral oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89B with a net income margin of 3.47%. Recent news highlights partnerships in AI and satellite communications, including an expanded collaboration with Microsoft and a defense-focused satellite venture with ICEYE.

The stock presents a valuation challenge with a high P/E of 75.09, though analyst consensus is bullish with a $17.50 price target. Upside potential is supported by AI infrastructure demand and strategic partnerships, but risks include competitive pressures, execution on growth initiatives, and volatile cash flows. The current price is well below the consensus target, indicating significant projected upside if growth catalysts materialize.

Zoetis Inc

Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.

The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NOK
92% Buy8% Sell
Avg holding period · 66 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About Nokia Corp

Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.

Read more on NOK →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →